Business Wire

Custom-built, medical research workflows advance pharma discovery

WALTHAM, Mass.--(BUSINESS WIRE)-- In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform.

This press release features... (continue reading...)

Builtfirst joins AppDirect to combine expertise and accelerate growth

SAN FRANCISCO--(BUSINESS WIRE)-- AppDirect, the world’s leading B2B commerce platform, today announced it has acquired Builtfirst, a leader in self-service marketplace platform technology. AppDirect has over a decade of experience in digital commerce. Adding the Builtfirst platform into AppDirect’s suite of solutions further expands AppDirect’s ability to help companies of all sizes with... (continue reading...)

Visionary entrepreneur, advisor and technologist, Mark Palmer brings strategic leadership.

BOSTON--(BUSINESS WIRE)-- AtScale, the premier provider of semantic layer solutions for analytics and Generative AI, is thrilled to announce the appointment of Mark Palmer to its distinguished Board of Directors. Palmer, a seasoned entrepreneur, advisor and technologist, brings a wealth of experience in tech innovation and strategic advisory, ensuring AtScale remains at the... (continue reading...)

Up to 176 daily flights to 27 destinations from Toronto-Pearson and Toronto-City airports

TORONTO--(BUSINESS WIRE)-- Porter Airlines is scheduled to offer travellers its most substantial summer schedule to date, featuring up to 176 daily flights to 27 destinations across North America taking off from Toronto. These flights will offer more passengers an elevated economy experience to more destinations than ever before.

This press release features multimedia. View... (continue reading...)

Alan Lotvin’s expertise in pharmacy benefit management and specialty pharmacy industries will inform n-Lorem’s efforts to identify and implement solutions to support nano-rare patient treatments

SAN DIEGO--(BUSINESS WIRE)-- n-Lorem, a nonprofit foundation, discovering, developing and providing experimental antisense oligonucleotide (ASO) medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life, today announced that Alan Lotvin, M.D.,... (continue reading...)